CA2437082A1 - Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes - Google Patents

Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes Download PDF

Info

Publication number
CA2437082A1
CA2437082A1 CA002437082A CA2437082A CA2437082A1 CA 2437082 A1 CA2437082 A1 CA 2437082A1 CA 002437082 A CA002437082 A CA 002437082A CA 2437082 A CA2437082 A CA 2437082A CA 2437082 A1 CA2437082 A1 CA 2437082A1
Authority
CA
Canada
Prior art keywords
hcv
antibody
cbh
peptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002437082A
Other languages
English (en)
French (fr)
Inventor
Steven K. H. Foung
Kenneth G. Hadlock
Zhen-Yong Keck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2437082A1 publication Critical patent/CA2437082A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109Hepatitis C virus; Hepatitis G virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002437082A 2000-12-01 2001-11-30 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes Abandoned CA2437082A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/728,720 2000-12-01
US09/728,720 US7091324B2 (en) 1998-11-05 2000-12-01 Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
PCT/US2001/045029 WO2002057314A2 (en) 2000-12-01 2001-11-30 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes

Publications (1)

Publication Number Publication Date
CA2437082A1 true CA2437082A1 (en) 2002-07-25

Family

ID=24928023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002437082A Abandoned CA2437082A1 (en) 2000-12-01 2001-11-30 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes

Country Status (6)

Country Link
US (2) US7091324B2 (enExample)
EP (1) EP1409682A2 (enExample)
JP (1) JP2004533991A (enExample)
AU (1) AU2002246545A1 (enExample)
CA (1) CA2437082A1 (enExample)
WO (1) WO2002057314A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
IL137522A (en) * 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
DE60231475D1 (de) 2001-01-12 2009-04-23 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
US7326536B2 (en) * 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
FR2850384A1 (fr) * 2003-01-28 2004-07-30 Centre Nat Rech Scient Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
CN103965301A (zh) 2003-04-01 2014-08-06 国家健康医学研究所 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
EP1797112B1 (en) * 2004-09-29 2010-07-21 The Administrators of the Tulane Educational Fund Inhibitors of hepatitits c virus
EP1669368A1 (en) * 2004-12-13 2006-06-14 Genoscience Use of peptides from the E2 protein of HCV for treating HCV infection
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
CN102197050A (zh) 2008-10-05 2011-09-21 小利兰斯坦福大学理事会 丙型肝炎抗体和其用途
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415491A (en) 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4683136A (en) 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
ATE207535T1 (de) 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5106726A (en) 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
ATE194844T1 (de) 1990-04-06 2000-08-15 Genelabs Tech Inc Hepatitis c-virus-epitope
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
EP0491077A1 (en) 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US5574132A (en) 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
DE69232859T2 (de) 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
PT773957E (pt) 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
US5985609A (en) 1994-11-04 1999-11-16 Mogam Biotechnology Research Institute Process for preparing hepatitis C virus envelope glycoproteins
US6020122A (en) 1995-06-07 2000-02-01 Abbott Laboratories Hepatitis C virus second envelope (HCV-E2) glycoprotein expression system
US6747136B2 (en) * 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6538114B1 (en) * 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
CA2305715A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
CA2339045A1 (en) * 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
JP2002528140A (ja) 1998-11-05 2002-09-03 ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ ヒトpan−hcvヒトモノクローナル抗体

Also Published As

Publication number Publication date
US20070032635A1 (en) 2007-02-08
WO2002057314A3 (en) 2003-05-30
EP1409682A2 (en) 2004-04-21
US7091324B2 (en) 2006-08-15
US20060104980A1 (en) 2006-05-18
JP2004533991A (ja) 2004-11-11
AU2002246545A1 (en) 2002-07-30
WO2002057314A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
US8114586B2 (en) Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US6692908B1 (en) Prevention and treatment of HCV infection employing antibodies that inhibit the interaction of HCV virions with their receptor
JP4105203B2 (ja) 診断用及び治療用の精製c型肝炎ウイルスエンベロープ蛋白
JP5642972B2 (ja) C型肝炎ウイルス(hcv)に対するヒト抗体およびその使用
Burioni et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments
CN113874394B (zh) 抗体
US7091324B2 (en) Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
HUT56883A (en) Process for producing virus polypeptides
JP4296174B2 (ja) G型肝炎ウイルスおよびその分子クローニング
WO2010047830A2 (en) Agents for hcv treatment
CA2738644A1 (en) Hepatitis c antibodies and uses thereof
US20030180284A1 (en) Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
Ray et al. Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus
WO2001021807A1 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
US6682909B2 (en) Immunogenic composition of hepatitis C and methods of use thereof
ES2377968T3 (es) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
US6924362B2 (en) Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
JP2000509966A (ja) C型肝炎ウイルス(hcv)e2抗原に特異的なヒトモノクローナル抗体
AU4143599A (en) Mimotopes of hypervariable region 1 of the E2 glycoprotein of HCV and uses thereof
da Silva Cardoso et al. Isolation and characterization of human monoclonal antibodies against hepatitis C virus envelope glycoproteins
KR20040041612A (ko) 합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도
JPH08504421A (ja) Hcvのc33領域由来のペプチド、該ペプチドに対する抗体及びhcvの検出方法
JP2007514413A (ja) C型肝炎ウイルス糖タンパク質をコードする新規配列
JP2004525885A (ja) 診断用および治療用の精製c型肝炎ウイルスエンベロープタンパク質

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued